SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+24.46%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$963M
AUM Growth
+$963M
(+11%)
Cap. Flow
-$20.1M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
42.67%
Holding
134
New
41
Increased
18
Reduced
32
Closed
26
Top Buys
| 1 |
Eli Lilly
LLY
|
$42.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$38.8M |
| 3 |
ONCR
Oncorus, Inc.
ONCR
|
$28.4M |
| 4 |
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
|
$26.1M |
| 5 |
C4 Therapeutics
CCCC
|
$14.6M |
Top Sells
| 1 |
Sanofi
SNY
|
$56.2M |
| 2 |
AbbVie
ABBV
|
$48.2M |
| 3 |
Amgen
AMGN
|
$28M |
| 4 |
Amicus Therapeutics
FOLD
|
$22.6M |
| 5 |
Sarepta Therapeutics
SRPT
|
$16.5M |
Sector Composition
| 1 | Healthcare | 79.61% |
| 2 | Technology | 10.28% |
| 3 | Industrials | 3.68% |
| 4 | Consumer Discretionary | 2.21% |
| 5 | Communication Services | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PAND
126
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| – | – | -95,000 | Closed | -$1.09M |
|
|
MYOK
127
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – | -81,000 | Closed | -$11M |
|
|
ARYBU
128
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| – | – | -499,000 | Closed | -$5.49M |
|
129
ADMA Biologics
ADMA
$4.12B
| – | – | -1,081,292 | Closed | -$2.58M |
|
130
Altimmune
ALT
$338M
| – | – | -243,000 | Closed | -$3.21M |
|
|
131
Amgen
AMGN
$155B
| – | – | -110,000 | Closed | -$28M |
|
132
Arvinas
ARVN
$568M
| – | – | -135,000 | Closed | -$3.19M |
|
133
Corbus Pharmaceuticals
CRBP
$115M
| – | – | 0 | – | – |
|